2 terminated, 1 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Completed 1 |
| Phase 2 | 1 | Terminated 1 |
Follow PLX51107: new trials by email Literature Review of PLX51107 trials Research Report on PLX51107
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD BRD4 Inhibitor PLX51107 - Acute Graft Versus Host Disease, Steroid Refractory Graft Versus Host Disease | Phase 1 / Phase 2 | Terminated | Hannah Choe, MD | 2 | 2022-04-19 | 2025-01-28 |
| PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Azacitidine, BRD4 Inhibitor PLX51107 - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Completed | M.D. Anderson Cancer Center | 43 | 2019-09-09 | 2022-10-31 |
| A Study of PLX51107 in Advanced Malignancies PLX51107 - Solid Tumors, Acute Myeloid Leukemia | Phase 1 | Terminated | Plexxikon | 50 | 2016-03-01 | 2018-12-24 |
Leukemia, Myeloid, Acute (2) · Myelodysplastic Syndromes (2) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Myeloproliferative Disorders (1)
Hannah Choe, MD (1) · M.D. Anderson Cancer Center (1) · Plexxikon (1)
United States (3)
Hannah Choe, MD (1) · Naveen Pemmaraju (1)
P30CA016672 (1), R01CA252469 (1)